Global T Cell Specific Surface Glycoprotein CD28 Market Size By Type (FPT-155, FR-104), By Application (Plaque Psoriasis, Solid Tumor), By Region, And Segment Forecasts, 2023 to 2032

The Global T Cell Specific Surface Glycoprotein CD28 Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.9 billion by 2031, growing at a CAGR of 12.7% during the forecast period of 2023–2031. CD28, a co-stimulatory molecule expressed on T cells, plays a pivotal role in initiating and regulating immune responses. Its significance in immuno-oncology, autoimmune disease research, and vaccine development has led to increased investments and innovation in targeted therapies, diagnostics, and biologics, propelling market expansion.

Drivers:

1. Growing Focus on Immuno-oncology Therapies:

The rise of immunotherapies—especially immune checkpoint inhibitors—has intensified research surrounding T cell activation pathways. CD28, being a central co-stimulatory receptor, is now a target for enhancing T cell responses in cancer treatment.

2. Increasing Prevalence of Autoimmune and Infectious Diseases:

The rising global burden of diseases involving immune dysregulation, including rheumatoid arthritis and HIV, has boosted interest in modulating CD28-related pathways for therapeutic benefits.

3. Advancements in Cell-based Therapeutics:

Innovations in CAR-T and TCR-T therapies that incorporate CD28 signaling domains have accelerated the adoption of CD28-targeted strategies across clinical research and therapeutic development.

Restraints:

1. Risk of Cytokine Release Syndrome:

CD28 superagonists have been associated with severe adverse reactions, such as cytokine storms, creating caution in therapeutic development and regulatory challenges for market players.

2. Complex Manufacturing and High Costs:

CD28-targeted therapies, particularly biologics and cell therapies, involve complex manufacturing processes and high production costs, limiting accessibility and scalability.

Opportunity:

1. Personalized Immunotherapy Development:

The push toward personalized medicine opens opportunities for integrating CD28-targeted therapies in precision immunotherapy pipelines, particularly for solid tumors and hematologic malignancies.

2. Expansion into Emerging Markets:

Rising healthcare investments in Asia-Pacific and Latin America, coupled with increasing clinical trial activity, are expected to open new avenues for CD28-targeted diagnostic and therapeutic solutions.

Market by System Type Insights:

Based on system type, the CD28 Monoclonal Antibodies segment accounted for the largest share in 2023. These antibodies are critical tools in immunological research and clinical studies due to their ability to modulate T cell activity. However, the CD28 Chimeric Antigen Receptor (CAR) Constructs segment is expected to witness the highest growth during the forecast period, driven by its pivotal role in enhancing CAR-T therapy efficacy and safety profiles.

Market by End-use Insights:

The Research Institutes & Academic Laboratories segment emerged as the leading contributor in 2023, supported by extensive use of CD28 reagents in basic immunology and translational research. The Biopharmaceutical Companies segment is anticipated to grow at a rapid pace due to rising clinical trials and the commercialization of novel CD28-modulated therapies for cancer and autoimmune disorders.

Market by Regional Insights:

North America dominated the T Cell Specific Surface Glycoprotein CD28 market in 2023, owing to the presence of major pharmaceutical companies, advanced research infrastructure, and high healthcare spending. Meanwhile, the Asia-Pacific region is forecasted to grow at the fastest CAGR through 2031, driven by increasing investments in biopharma R&D and a growing patient pool requiring advanced immunotherapies.

Competitive Scenario:

Key players operating in the global CD28 market include Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., Miltenyi Biotec, Abcam plc, Gilead Sciences, and Lonza Group. Companies are engaging in collaborations, licensing deals, and pipeline expansions to strengthen their foothold in this niche but rapidly evolving domain.

Recent Developments:

In 2024, Amgen Inc. launched a new CD28-modified CAR-T therapy targeting hematologic malignancies, demonstrating improved efficacy and lower cytokine toxicity.

In 2023, Bio-Techne Corporation unveiled a suite of CD28 agonistic reagents aimed at supporting T cell expansion in ex vivo applications.

In 2022, Thermo Fisher Scientific expanded its licensing agreements with multiple biotech startups for the commercialization of CD28 co-stimulatory pathway modulators.

Scope of Work – Global T Cell Specific Surface Glycoprotein CD28 Market

FAQs:

1) What is the current market size of the Global T Cell Specific Surface Glycoprotein CD28 Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global T Cell Specific Surface Glycoprotein CD28 Market?

A key driver is the growing emphasis on CD28’s role in immuno-oncology and cell therapy development.

3) Which is the largest region during the forecast period in the Global T Cell Specific Surface Glycoprotein CD28 Market?

North America holds the largest market share due to robust R&D infrastructure and clinical activity.

4) Which segment accounted for the largest market share in the Global T Cell Specific Surface Glycoprotein CD28 Market?

The Monoclonal Antibodies segment led the market in 2023.

5) Who are the key market players in the Global T Cell Specific Surface Glycoprotein CD28 Market?

Major players include Amgen Inc., Bio-Techne Corporation, Thermo Fisher Scientific, and Novartis AG.